A Relaxin receptor agonist drug (RRA01) for the acute heart failure treatment is developed by the...

50.1K

Verified Solution

Question

Basic Math

A Relaxin receptor agonist drug (RRA01) for the acute heartfailure treatment is developed by the Sunny Pharmaceutical Company.It is a publicly traded company. The reduction of cardiovasculardeath (mortality) was used as the end point (results of theresearch) for this investigation. The null hypothesis is “there isno difference in the cardiovascular mortality reduction betweenpatients who received RRA01 (treatment group) and those who did notreceive RRA01 (control group). Discuss the impact (on the companyand/or on the patients) of the following two possible clinicaltrial results to the Sunny Pharmaceutical Company, staff of thecompany, and the patients. 1. p = 0.002 as the hypothesis testresults 2. p = 0.3 as the hypothesis test results.

Answer & Explanation Solved by verified expert

3.9 Ratings (755 Votes)

A Relaxin receptor agonist drug RRA01 for the acute heart failure treatment is developed by the Sunny Pharmaceutical Company It is a publicly traded company The reduction of cardiovascular death mortality was used as the end point results of the research for this investigation The See Answer

Get Answers to Unlimited Questions

Join us to gain access to millions of questions and expert answers. Enjoy exclusive benefits tailored just for you!

Membership Benefits:

Unlimited Question Access with detailed Answers
Zin AI - 3 Million Words
10 Dall-E 3 Images
20 Plot Generations
Conversation with Dialogue Memory
No Ads, Ever!
Access to Our Best AI Platform: Flex AI - Your personal assistant for all your inquiries!

Become a Member